DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
REFERENCES
- Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous
Stem Cell Transplant vs Single Transplant on Event-Free Survival in
Patients With High-Risk Neuroblastoma: A Randomized Clinical
Trial. JAMA . 2019;322:746-755.
- Ladenstein R, Pötschger U, Pearson ADJ, et al; SIOP Europe
Neuroblastoma Group (SIOPEN). Busulfan and melphalan versus
carboplatin, etoposide, and melphalan as high-dose chemotherapy for
high-risk neuroblastoma (HR-NBL1/SIOPEN): an international,
randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol .
2017;18:500-514.
- Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for
children with high-risk neuroblastoma treated on a randomized trial of
myeloablative therapy followed by 13-cis-retinoic acid: a children’s
oncology group study. J Clin Oncol. 2009;27:1007-1013.
- Valteau-Couanet D, Le Deley MC, Bergeron C, et al. Long-term results
of the combination of the N7 induction chemotherapy and the
busulfan-melphalan high dose chemotherapy. Pediatr Blood
Cancer . 2014;61:977-981.
- Bansal D, Totadri S, Chinnaswamy G, et al. Management of
Neuroblastoma: ICMR Consensus Document. Indian J Pediatr.
2017;84:446-455 .
- Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for
patients with stage 4 neuroblastoma who were older than 18 months at
diagnosis: a report from a single institute in Shanghai, China.J Cancer Res Clin Oncol. 2017;143:1327-1335.
- Jain R, Hans R, Totadri S, et al. Autologous stem cell transplant for
high-risk neuroblastoma: Achieving cure with low-cost
adaptations. Pediatr Blood Cancer . 2020;67:e28273.
- Aksoylar S, Varan A, Vergin C, et al. Treatment of high-risk
neuroblastoma: National protocol results of the Turkish Pediatric
Oncology Group. J Cancer Res Ther. 2017;13:284-290.
- Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome
of neuroblastoma with conventional chemotherapy in children older than
one year: a 15 y experience. Indian Pediatr. 2008;45:135-139.
- Parikh NS, Howard SC, Chantada G, et al. International Society of
Pediatric Oncology. SIOP-PODC adapted risk stratification and
treatment guidelines: Recommendations for neuroblastoma in low- and
middle-income settings. Pediatr Blood Cancer.2015;62:1305-1316.
- Koshy A, Jain R, Srinivasan R, et al. Cytopathological spectrum of
peripheral neuroblastic tumours in fine needle aspiration cytology and
categorisation as per International Neuroblastoma Pathology
Classification. Cytopathology. 2019;30:634-643.
- WHO Anthro (version 3.2.2) and macros. Geneva: WHO; 2011.
http://www.who.int/childgrowth/software/en/. Accessed
January 10, 2020.
- WHO AnthroPlus for Personal Computers: Software for Assessing Growth
of the World’s Children and Adolescents. Geneva: WHO; 2009.
http://www.who.int/growthref/tools/en/. Accessed January
12, 2020.
- WHO Global Database on Child Growth and Malnutrition. Geneva: WHO;
2016.
http://www.who.int/nutgrowthdb/about/introduction/en/.
Accessed January 12, 2020.
- High-risk neuroblastoma study 1 of SIOP-Europe (SIOPEN)/UK version/
August 2002/amended July 2007
- Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the
international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol. 1993;11:1466-1477.
- Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage
with autologous stem-cell transplantation in high-risk neuroblastoma
consolidated by anti-GD2 immunotherapy and isotretinoin.Oncotarget. 2016;7:4155-4166.
- Van Heerden J, Hendricks M, Geel J, et al. Overall survival for
neuroblastoma in South Africa between 2000 and 2014. Pediatr
Blood Cancer. 2019;66:e27944.
- Agarwala S, Mandelia A, Bakhshi S, et al. Neuroblastoma: outcome over
a 14 y period from a tertiary care referral Center in India. J
Pediatr Surg. 2014;49:1280-1285.
- Lau SCD, Unni MNM, Teh KH, et al. Autologous stem cell transplantation
following high-dose chemotherapy in children with high-risk
neuroblastoma: Practicality in resource-limited
countries. Pediatr Blood Cancer . 2020;67:e28176.
- Radhakrishnan V, Raja A, Dhanushkodi M, Ganesan TS, Selvaluxmy G,
Sagar TG. Real World Experience of Treating Neuroblastoma: Experience
from a Tertiary Cancer Centre in India. Indian J Pediatr .
2019;86:417-426.
- Zhang YT, Chang J, Xu HM, Li YN, Zhong XD, Liu ZL. Treatment of
Neuroblastoma with a Novel Delayed Intensification
Chemotherapy. Indian J Pediatr . 2019;86:126-131.
- Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for
patients with stage 4 neuroblastoma who were older than 18 months at
diagnosis: a report from a single institute in Shanghai,
China. J Cancer Res Clin Oncol . 2017;143:1327-1335.
- Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM.
Neuroblastoma in Iran: an experience of 32 years at a referral
childrens hospital. Asian Pac J Cancer Prev . 2013;14:2739-2742.
- Moussa E, Fawzy M, Younis A, et al. Combined Treatment Strategy and
Outcome of High Risk Neuroblastoma: Experience of the Children’s
Cancer Hospital-Egypt. Journal of Cancer Therapy .
2013;4:1435-1442.
- El-Sayed MI, Ali AM, Sayed HA, Zaky EM. Treatment results and
prognostic factors of pediatric neuroblastoma: a retrospective
study. Int Arch Med . 2010;3:37.
- Parise IZ, Haddad BR, Cavalli LR, et al. Neuroblastoma in southern
Brazil: an 11-year study. J Pediatr Hematol Oncol .
2006;28:82-87.
- Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones
DR. High dose melphalan in the treatment of advanced neuroblastoma:
results of a randomised trial (ENSG-1) by the European Neuroblastoma
Study Group. Pediatr Blood Cancer . 2005;44:348-357.
- Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with
autologous stem-cell rescue versus oral maintenance chemotherapy as
consolidation treatment in patients with high-risk neuroblastoma: a
randomised controlled trial. Lancet Oncol . 2005;6:649-658.
- Amoroso L, Erminio G, Makin G, et al.
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma
Patients Failing to Achieve a Complete Metastatic Response to Rapid
COJEC: A SIOPEN Study. Cancer Res Treat . 2018;50:148-155.
- Elliott M, Gray J, Tweddle D, et al. Statement from CCLG Neuroblastoma
SIG: Treatment and management of patients with high-risk
neuroblastoma. March 2019.
https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/HR_NB_-_March_2019.pdf.Accessed May 20, 2020.
- Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen
incorporating pharmacokinetically guided topotecan for treatment of
newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group
study. J Clin Oncol . 2011;29:4351-4357.
- Rujkijyanont P, Photia A, Traivaree C, et al. Clinical outcomes and
prognostic factors to predict treatment response in high risk
neuroblastoma patients receiving topotecan and cyclophosphamide
containing induction regimen: a prospective multicenter
study. BMC Cancer . 2019;19:961.
- Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel,
topotecan, and topotecan-cyclophosphamide in children with untreated
disseminated neuroblastoma treated in an upfront phase II
investigational window: a pediatric oncology group study. J Clin
Oncol . 2004;22:4119-4126.
- Garaventa A, Luksch R, Biasotti S, et al. A phase II study of
topotecan with vincristine and doxorubicin in children with
recurrent/refractory neuroblastoma. Cancer . 2003;98:2488-2494.
- Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and
standard induction chemotherapy for patients aged over 1 year with
stage 4 neuroblastoma: a randomised trial. Lancet Oncol .
2008;9:247-256.